About Peter U. Nwangwu, R. PH., M. Sc., Pharm. D., Ph. D.



In January 1972, young Peter Nwangwu came to the United States for his college education at the University of Nebraska at Lincoln. He placed out of many courses by challenge exams, and was elected into the university’s honor roll beginning from his first year, and also into the national scholastic honor society, Phi Eta Sigma, the exclusive academic honorary for selected men in American universities. Nwangwu was an extremely focused and intelligent student. He made history at Nebraska when he became the first student to earn a Bachelor’s degree from the University of Nebraska after two years of undergraduate studies. He earned a master’s degree from the department of Medicinal Chemistry and Pharmacognosy and the Department of Pharmacodynamics and Toxicology in 1976. His doctoral training at the University of Nebraska Medical Center was in interdisciplinary medical sciences, with special focus on Pharmacology, which he pursued together with the professional doctor of pharmacy degree. He made even more history when he became the first student at the university to earn the Pharm.D. and Ph.D. degrees simultaneously. He has advanced training, degree, and productive research experience in every area of pharmacy. He was the third person in the United States to earn the Pharm. D., Ph. D. degree, only behind Gerald E. Schumacher who served as Dean of Pharmacy at Northeastern University in the late 1970’s/80’s and Harry Rosenberg who currently serves as President at Roseman University of Health Sciences, Nevada (formerly the University of Southern Nevada).

He accepted a position as Director of Clinical Research and Assistant Professor of Pharmacology and Toxicology at Florida A & M University in 1979. In 1981 he was appointed Associate Professor of Pharmacology and Toxicology at St. John’s University in New York. He joined the world headquarters of multibillion dollar multinational drug manufacturing company, Ayerst Laboratories, in Manhattan New York as Clinical Research Monitor in 1983. He started the first pharmaceutical manufacturing company owned by a black man in the United States, and served on the board of directors of several companies in the U.S.  He has been nominated three different times by his professional peers as candidate to serve as President of three universities in the United States: University of Wisconsin-Eau Claire, Alabama A & M University, and Albany State University, Albany, Georgia, all in 2005. From 2006 to 2011, he served as Executive Assistant to the President at the University of Nigeria (over 40,000 students and 2000 academic staff) and full Professor of Pharmacology, Toxicology, and Clinical Pharmacy. He worked with and reported directly to the President and was a key member of the President’s administrative cabinet. He assisted the President, and collaborated with senior University leadership including deans, and Directors, to guide the school in implementing and advancing the strategic plans of the University. In addition, Nwangwu served simultaneously as the Chief Development Officer of the University, and also as the President and CEO of the University of Nigeria Research and Economic Development (UNRED) Foundation, Inc.

In a historical reference book, “The Nigerian-Americans”, published in America by Greenwood Press, authored by Professor Ogbaa, Peter Nwangwu, along with Haakeem Olajuwon and Phillip Emeagwali were among the twelve Nigerian-born Americans in American History who were selected and documented as Nigerian-born Americans who have made the greatest positive impact and contributions to the American society. He is an outstanding and very accomplished pharmacist, medical scientist, inventor, educator, and entrepreneur. Specific examples of meritorious research productivity, and significant inventions in the field of Medicine, Pharmacy, and Pharmaceutical Research and Development by Professor Nwangwu include:

●Invented a new technique for screening antiarrhythmic drugs which received worldwide acceptance and became popular worldwide; the technique is still used in several pharmaceutical companies and pharmacology laboratories as a standard screening technique for antiarrhythmic drugs, “A rapid in vivo Technique for Preliminary screening of Antiarrhythmic Agents in Mice” Arch. Int. Pharmacodyn Therap. 229, 219 (1977).

●Developed and characterized seven new antiarrhythmic drugs which are protected by U.S. patents. Relevant research publications in major world scientific literature by Professor Nwangwu on the discovery of these seven new drugs include: J. Pharm. Pharmacol 46, 301 (1979); Toxicology 16, 73 (1980); Current Therapeutic Research 29: 416 (1981); J. Cardiovasc Pharmacol 4, 124 (1982); Current Therapeutic Research 30, 479 (1981); J. Med. Chem. 22, 110 (1979).

●Invented a new technique for identification of time of Myocardial Infarction Employing TC-99 pyrophosphate, Current Therapeutic Research 30: 122 (1981).

●Documented and published the first in vivo murine ventricular tachycardia in a single surface electrocardiogram lead, which has become a relevant murine model of human cardiomyopathy for significant studies in cardiovascular disease worldwide.  As the first Medical Scientist in the world to discover and publish in vivo murine ventricular tachycardia in a single surface electrocardiogram lead, Professor Nwangwu is widely quoted by Medical Scientists worldwide who employ his original research technique and breakthrough as a murine model of human cardiomyopathy for studies in cardiovascular disease worldwide, including scientists at Harvard medical school and other Ivy league schools.

In a recent article by scientists in peer reviewed European journal, Turkish Journal of Politics, Vol. 2, No. 2, p. 81, winter 2011, the scientists cited Nwangwu by name as, “…a world renowned clinical Pharmacologist who ranks among the top ten Pharmacologists in the world.”

 Nwangwu has over 30 years of experience in pharmaceutical research and development, including 15 years as President, CEO, and Chairman of the Board of pharmaceutical manufacturing companies in the United States, Punlabs Quality Products, Inc. and Ebony Pharmaceutical Manufacturing, Inc. He has very strong food and drug regulatory experience, including serving for many years as a member of the technical and drug regulatory committee of the National Pharmaceutical Alliance, Washington, D.C. He has extensive experience with United States Food and Drug Administration. His book, “Concepts and Strategies in New Drug Development,” is used in pharmaceutical industries worldwide, and as a textbook in some Clinical Pharmacology graduate training programs in U.S. universities.  The publisher of the book, Praeger Publishers, New York, described it as their best seller in New Drug Development in the United States, Canada, and Europe.  Nwangwu has served on the editorial board of four different reputable International Journals in pharmaceutical research.  He is a potent fund raiser, and has extensive experience and the necessary contacts for securing research grants; his research has been funded significantly by the U.S. National Institute of Health (NIH). He still serves as Member of the prestigious U.S. scientific and technology think-tank group of experts, “The Council of Healthcare and Biotechnology Advisors,” Gerson Lehrman Group, New York, New York, which is a select group of distinguished scientific and technical professionals carefully assembled by the Wall Street investment advisory firm, Gerson Lehrman Group, to provide paid healthcare and biotechnology market research, industry recommendations, and consulting services worldwide. Nwangwu has extensive experience in new drug development, and Clinical Trials of New Drugs. He is distinguished, credible and reputable because of his inventions and books which are used worldwide.

In addition to these, Professor Nwangwu is a devout priest of the Anglican Church, with a deep and reverent fear of God. He practices his belief and faith; therefore, he is utterly dependable and honorable.  His life is impeccable and above reproach. He also served as the Associate Chaplain of Christ Church Chapel, the large multi-denominational Church of Anglicans, Methodists, Presbyterians, and other Protestant denominations at the University of Nigeria. Nwangwu has received many awards and honors, including being listed in more than twenty biographical reference books.  In September 2006, Nwangwu was honored in the United States as the recipient of “The 2006 Congressional Medal of Distinction”.  In 2005, he was decorated with three meritorious awards; he was named the recipient of “The 2005 President Ronald Reagan Republican Gold Medal”, by the National Republican Congressional Committee, Washington D.C.; he was named “Man of the Year 2005”, by the American Biographical Institute, Raleigh North Carolina; and he was also named “Businessman of the Year 2005”, by the United States Business Advisory Council, Washington, D.C.  He received a letter from United States Congressman Tom Reynolds inviting him to dinner with President Bush in Washington D.C. to celebrate his awards, which took place on March 16, 2006. In May, 2008, his alma mater in the United States selected Nwangwu as “The 2008 Outstanding International Alumnus of the University of Nebraska”. Only one person in the world is selected for this award.  Nwangwu was the second person to receive the award since it was established at the University.

He serves on the board of Directors of Fanafi Worldwide Ventures, Ltd., and Pan African Capital, Plc. He was elected unanimously as the Presidential candidate for the African Democratic Congress (ADC) political party and ran for President of Nigeria in the 2011 Nigerian Presidential elections. 

Peter is married to Patience, and they have five sons and one daughter.